Friday, May 9, 2008
Management
Avlar's board and management exhibit
combined skills covering technical, financial, general management,
sales, marketing and new business development and have extensive
experience in the biotechnology and healthcare sectors in:
- creating and developing biotechnology companies
- hands on management experience across the sector
- securing finance for both early and later stage biotechnology companies
- effecting major corporate alliances and strategic partnering
- flotations, mergers and acquisitions
- providing strategic advice to a number of major companies
- producing technical experts' reports
- implementing product development strategies
|
Executive Directors | |
|
| |
 |
Alan Goodman (CEO and Finance Director) Over the last 18 years Alan Goodman has founded or co-founded many biotechnology and healthcare companies, including Agricultural Genetics Company, Medeva plc, Chiroscience Group plc, Peptide Therapeutics (now Acambis plc), Oxford BioMedica plc, CeNeS Pharmaceuticals plc, Core Group plc and Amura Limited. He was non-executive Chairman of Oxford BioMedica plc and is currently chairman of CeNeS Pharmaceuticals plc. |
|
| |
 |
Daniel Roach (Investment Director)
Dr Daniel Roach came to Cambridge in 1985 to join PA Consulting
Group, becoming Business Development Manager for the Biotechnology
Group. In 1993, he joined Advanced Technology Management Limited (ATM),
a company established by Alan Goodman which has been involved in
forming and seeding nine companies, seven of which subsequently listed
on Stock Exchanges - Acambis, Chiroscience, CeNeS, Core, Lidco, Oxford
Biomedica and Salix. He was a co-founder of Peptide Therapeutics (now Acambis) in 1993 where he was Commercial Director, CeNeS in 1996 where he was CEO from 1997-2002, Amura in 1997 and Avlar in 1998. He is currently an investment director of Avlar, the ATM group of companies, Medical Device Innovations and Purely Proteins. He has recently been appointed Entrepreneur in Residence at the Centre for Entrepreneurial Learning and to the Greater Cambridge Partnership (GCP) Operating Board. In addition, he has been a board trustee of the Babraham Institute and Chairman of ERBI. He was one of the first students to read biochemistry at the University of Swansea and has a PhD in enzymology from Bath University, funded by Porton Down. |
|
| |
 |
Martyn Collett (Business Development Director)
Martyn Collett has a BSc in biochemistry, an MSc in biochemical
engineering and an MBA. He has worked in the healthcare industry for 24
years with Wyeth Ayerst, GD Searle, PA Consulting Group, Quadrant
Healthcare, CeNeS Pharmaceuticals and Medical Device Innovations. For
the last 10 years Martyn has worked with small companies in business
and corporate development roles. He has extensive experience of
licensing and mergers and acquisitions. |
|
| |
 |
Catherine Beech (Clinical Director) Catherine was a founding Partner of Cambridge Gateway Fund, an early stage life sciences and technology fund investing in the UK. Her background is in the multi national pharmaceutical industry, specialising in clinical development. She holds a medical degree from the University of Birmingham. |
|
Non-executive Directors | |
|
| |
|
|
Alan Smith CPFA (Non-Executive Chairman)
Senior management experience, including Group Finance Director of
Anglian Water Authority, Anglian Water plc, Group Managing Director of
Anglian Water. He is Chairman of Acambis plc. |
|
| |
|
|
David Needham PhD (Non-Executive Director)
Was a Partner at Alta Berkeley. Led or managed over 25 high
technology investments. He holds a PhD in High Speed Aerodynamics from
Imperial College London. |
